A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder

Introduction and Objectives. MicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict...

Full description

Saved in:
Bibliographic Details
Published in:Disease markers 2018-01, Vol.2018 (2018), p.1-6
Main Authors: Saito, Kenkichi, Tanda, Naoki, Minami, Koichiro, Hirano, Hajime, Nomi, Hayahito, Kato, Ryuji, Hayashi, Tetsuya, Azuma, Haruhito, Uchimoto, Taizo, Takai, Tomoaki, Takahara, Kiyoshi, Komura, Kazumasa, Ibuki, Naokazu, Akao, Yukihiro, Uehara, Hirofumi, Inamoto, Teruo, Yoshikawa, Yuki
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Biomarkers
Biomarkers, Tumor - genetics
Biomarkers, Tumor - metabolism
Bladder
Bladder cancer
Cancer
Cancer therapies
Carcinoma
Carcinoma - genetics
Carcinoma - metabolism
Carcinoma - pathology
Chemotherapy
Deregulation
Genetic aspects
Genomes
Genomics
Humans
HyperText Markup Language
Male
Medical prognosis
Medical research
Medicine
Medicine, Experimental
Metastasis
MicroRNA
MicroRNAs
MicroRNAs - genetics
MicroRNAs - metabolism
miRNA
Patient outcomes
Patients
Phenotypes
Prognosis
Rank tests
Ribonucleic acid
Risk
RNA
Servers
Survival
Survival Analysis
Systematic review
Transcriptome
Urinary Bladder Neoplasms - genetics
Urinary Bladder Neoplasms - metabolism
Urinary Bladder Neoplasms - pathology
Urothelial carcinoma
Urothelium - metabolism
Urothelium - pathology
Web portals
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction and Objectives. MicroRNA (miRNA) expression is altered in urologic malignancies, including urothelial carcinoma of the bladder (UCB). Individual miRNAs have been shown to modulate multiple signaling pathways that contribute to BC. To identify a panel of miRNA signature that can predict aggressive phenotype from normal nonaggressive counterpart using miRNA expression levels and to assess the prognostic value of this specific miRNA markers in patients with UCB. Methods. To determine candidate miRNAs as prognostic biomarkers for dividing aggressive type of UCB, miRNA expression was profiled in patients’ samples with an aggressive phenotype or nonaggressive phenotype using 3D-Gene miRNA labeling kit (Toray, Japan). To create a prognostic index model, we used the panel of 9-miRNA signature based on Cancer Genome Atlas (TCGA) data portal (TCGA Data Portal (https://tcgadata.nci.nih.gov/tcga/tcgaHome2.jsp)). miRNA expression data and corresponding clinical data, including outcome and staging information of 84 UCB patients, were obtained. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results. Deregulation of nine miRNAs (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-145-5p, hsa-miR-4324, hsa-miR-34b-5p, hsa-miR-29c-3p, hsa-miR-135a-3p, and hsa-miR-33b-3p) was determined in UCB patients with aggressive phenotype compared with nonaggressive subject. To validate the prognostic power of the nine-signature miRNAs using the TCGA dataset of bladder cancer, the survival status and tumor miRNA expression of all 84 TCGA UCB patients were ranked according to the prognostic score values. Of nine miRNAs, six were associated with high risk (hsa-miR-99a-5p, hsa-miR-100-5p, hsa-miR-125b-5p, hsa-miR-4324, hsa-miR-34b-5p, and hsa-miR-135a-3p) and three were shown to be protective (hsa-miR-145-5p, hsa-miR-29c-3p, and hsa-miR-33b-3p). Patients with the high-risk miRNA signature exhibited poorer OS than patients expressing the low-risk miRNA profile (HR = 7.05, p
ISSN:0278-0240
1875-8630
DOI:10.1155/2018/5468672